Health ❯Obesity

Treatment Options

Medications GLP-1 Medications Injectable Medications Pharmaceutical Treatments Clinical Studies Incretin Medications Pharmaceuticals Drug Therapies Patient Access Weight-Loss Drugs Clinical Trials Drug Development Non-Invasive Procedures Weight Loss Strategies Weight-loss Injections Prescription Drugs Weight Loss Drugs Drug Efficacy

Pfizer Halts Development of Danuglipron After Liver Safety Concerns

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

AbbVie Enters Obesity Drug Market with $2.2 Billion Licensing Deal

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

Novo Nordisk Reports Doubling Wegovy Sales, Projects Slower Growth in 2025

GLP-1 Drugs Revolutionize Obesity Treatment While Raising Questions About Risks and Costs

Growing Demand for Weight-Loss Drugs in the UK Raises Safety and Accessibility Concerns

Nestle Introduces Protein Shot to Support Weight Loss and Hunger Management

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism

New Weight Loss Drug Shows Promise Without Nausea

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

FDA Reconsiders Ban on Compounded Versions of Eli Lilly's Weight Loss Drug

Doctors Question Safety and Efficacy of GLP-1 Supplements and Drugs for Weight Loss

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial

Viking Therapeutics Advances Weight-Loss Drug, Shaking Up Market Leaders

Surge in GLP-1 Drugs for Weight Loss Sparks Concerns Over Diabetes Treatment